And women will need easy access to the shots every eight weeks,which must be given by a medical professional. The trial researchers sent transportation for the women and managed to retain 98 percent of the participants, she said. The trial compared the injected drug, called cabotegravir, with Truvada in 3,223 participants in 20 sites across seven countries in sub-Saharan Africa. Of the women who received Truvada, 34 became infected with H.I.V. during the trial, compared with just four of the women receiving the injections; two of those four women had stopped taking the injections, Dr. Smith said.

Source: International New York Times November 09, 2020 06:56 UTC